Curis cancer diagnosis fails to encounter trials target
Curis cancer diagnosis fails to encounter trials target
Curis Inc., the cancer-focused biotech in Cambridge, voiced currently which GDC-0449, the Hedgehog pathway inhibitor which fights cancer, did not encounter the goals for the Phase 2 clinical hearing mutually instituted by Roche as well as Genentech Inc.